Clinical trials
Leiomyoma trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
20 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2012 | 2 |
| 2013 | 1 |
| 2015 | 2 |
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Recruiting | 3 |
| Terminated | 3 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| PregLem SA | 3 |
| Assistance Publique - Hôpitaux de Paris | 2 |
| University Hospital, Bordeaux | 2 |
| ASSOCIATION POUR LE DEVELOPPEMENT EN FECONDATION IN VITRO | 1 |
| Assistance Publique Hopitaux De Marseille | 1 |
| Centre Hospitalier Intercommunal Creteil | 1 |
| Ethicon, Inc. | 1 |
| Fondation Hôpital Saint-Joseph | 1 |
| Gynesonics | 1 |
| InSightec | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leiomyoma | 20 |
| Hemorrhage | 2 |
| Menorrhagia | 2 |
| Uterine Neoplasms | 2 |
| Endometriosis | 1 |
| Genital Diseases, Female | 1 |
| Infertility, Female | 1 |
| Myofibroma | 1 |
| Myoma | 1 |
| Ovarian Cysts | 1 |
Trials
Showing 76 to 20 of 20. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.